Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study.

@article{Salvarani2003TreatmentOR,
  title={Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study.},
  author={Carlo Salvarani and Fabrizio Cantini and Laura Niccoli and Maria Grazia Catanoso and Pierluigi Macchioni and Lia Pulsatelli and Angela Anna Padula and Ignazio Olivieri and Luigi Boiardi},
  journal={The Journal of rheumatology},
  year={2003},
  volume={30 4},
  pages={
          760-3
        }
}
OBJECTIVE To investigate whether infliximab has a steroid-sparing effect in the treatment of patients with polymyalgia rheumatica (PMR) who are resistant to corticosteroid (CS) therapy and have had CS-related side effects. METHODS In a pilot study, infliximab 3 mg/kg was administered at weeks 0, 2, and 6 in 4 patients with relapsing PMR who were not able to reduce their prednisone dose below 7.5-12.5 mg/day and who had experienced multiple vertebral fractures. The patients were regularly… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS

Update on polymyalgia rheumatica.

  • European journal of internal medicine
  • 2013
VIEW 1 EXCERPT
CITES BACKGROUND